Indoximod

Phase 2Small molecule

NNewLink Genetics Corporation

Indoximod is one of 231 small molecule programs targeting Brain Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

230

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain CancerActive, not recruiting

Metastatic MelanomaActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Brain CancerPhase 1

Active, not recruiting

Metastatic MelanomaPhase 1/Phase 2

Active, not recruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tykerb

GSK

Preclinical

80 2

Tecentriq

Roche

Preclinical

36 3

Trodelvy

Gilead

Preclinical

37 4

Halaven

Eisai

Preclinical

38 5

Indoximod

NNewLink Genetics Corporation

Phase 2

1 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Newly Diagnosed

NCT04049669

Q3 2028

Phase 1Recruiting

Brain Cancer

NCT05106296

Clinical

Trials by Indication[1]

Malignant Brain Tumors2 trials

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Completed·NNewLink Genetics Corporation·Phase 1·NCT02502708·81 enrolled

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Completed·NNewLink Genetics Corporation·Phase 1/2·NCT02052648·160 enrolled

Metastatic Melanoma2 trials

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Completed·NNewLink Genetics Corporation·Phase 1/2·NCT02073123·132 enrolled

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma

Terminated·NNewLink Genetics Corporation·Phase 2·NCT03301636·21 enrolled

Brain Cancer1 trial

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Recruiting·TTheodore S. Johnson·Phase 1·NCT05106296·37 enrolled

Metastatic Prostate Cancer1 trial

Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01560923·47 enrolled

Breast Cancer1 trial

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

Completed·NNewLink Genetics Corporation·Phase 2·NCT01792050·169 enrolled

3 more indications

Pancreatic Cancer1 trial

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Completed·NNewLink Genetics Corporation·Phase 1/2·NCT02077881·157 enrolled

Newly Diagnosed1 trial

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

Active, not recruiting·TTheodore S. Johnson·Phase 2·NCT04049669·130 enrolled

Non-Small Cell Lung Cancer1 trial

Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

Terminated·NNewLink Genetics Corporation·Phase 1·NCT02460367·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Indoximod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Indoximod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Indoximod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NewLink Genetics Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNewLink Genetics Corporation

Indoximod

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2028

Trials by Indication[1]

Malignant Brain Tumors2 trials

Metastatic Melanoma2 trials

Brain Cancer1 trial

Metastatic Prostate Cancer1 trial

Breast Cancer1 trial

Pancreatic Cancer1 trial

Newly Diagnosed1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News